ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 815

Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis

Koji Fukuda1, Yasushi Miura 2, Shinya Hayashi 1, Toshihisa Maeda 3 and Ryosuke Kuroda 1, 1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 2Division of Orthopedic Science, Department Of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, 3Matsubara Mayflower Hospital, Kobe, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fas ligand, Fibroblasts, microarray assay and Gene Expression, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S079: RA – Etiology & Pathogenesis I (815–820)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Fas ligand (FasL) is a member of tumor necrosis factor superfamily (TNFSF6) and reported to contribute to synovial hyperplasia of rheumatoid arthritis (RA). Apoptosis through Fas/FasL pathway of RA synovial cells was inhibited by pro-inflammatory cytokines present within the synovium. We previously reported that decoy receptor 3 overexpressed in rheumatoid synovial fibroblasts (RA-FLS) stimulated by TNFα protects the cells from Fas-induced apoptosis. In this study, we investigated the gene expression profiles regulated by FasL in RA-FLS to reveal how FasL is involved in the pathogenesis of RA.

Methods: Primary cultured RA-FLS were incubated with either 1000 ng/ml of recombinant human FasL protein or phosphate buffered saline as unstimulated control diluted with Opti-MEM reduced serum medium for 12h. Gene expressions were detected by microarray assay (Human Genome U133 Plus 2.0, GeneChip® 3′ Expression Array; Thermo Fisher Scientific).

Results: Microarray data analysis revealed that FasL up-regulated or down-regulated the expression of various genes in RA-FLS. The most up-regulated 3 genes by FasL were dual specificity phosphatase 6 (DUSP6; fold change, 34.6), epiregulin (EREG; fold change, 29.2) and interleukin11 (IL-11; fold change, 25.3). DUSP6 regulates CD4+ T-cell activation and differentiation by inhibiting the T-cell receptor-dependent extracellular signal-regulated kinases 1 and 2 activations. EREG is increased in patients with RA and associated with the development of cytokine-induced arthritis. IL-11 regulates the growth and development of hematopoietic stem cells and decreases the pro-inflammatory cytokines and nitric oxide productions. The most down-regulated 3 genes by FasL were angiopoietin-like 7 (ANGPTL7; fold change, 11.6), protein inhibitor of activated STAT2 (PIAS2; fold change, 11.3) and growth differentiation factor 5 (GDF5; fold change, 11.1). ANGPTL7 is pro-angiogenic factor and promotes pro-inflammatory responses through the P38 signaling pathway. PIAS proteins inhibit the activated STAT and are involved in the pathogenesis of RA. GDF5 is associated with joint destruction of patients with OA and RA. The function of regulated genes included transcriptional activator activity, positive regulation of metabolic process, positive regulation of cellular metabolic process, positive regulation of macromolecule metabolic process, positive regulation of nitrogen compound metabolic process, regulation of phosphorylation, positive regulation of biological process, regulation of phosphate metabolic process, regulation of MAPK cascade, and regulation of multicellular organismal process.

Conclusion: FasL regulates the expression of various genes in RA-FLS. FasL may affect the pathogenesis of RA by regulating gene expression of RA-FLS.


Disclosure: K. Fukuda, None; Y. Miura, None; S. Hayashi, None; T. Maeda, None; R. Kuroda, None.

To cite this abstract in AMA style:

Fukuda K, Miura Y, Hayashi S, Maeda T, Kuroda R. Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/expression-profiling-of-genes-in-rheumatoid-fibroblast%e2%80%91like-synoviocytes-regulated-by-fas-ligand-using-cdna-microarray-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-profiling-of-genes-in-rheumatoid-fibroblast%e2%80%91like-synoviocytes-regulated-by-fas-ligand-using-cdna-microarray-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology